Literature DB >> 31045670

Bipolar Fresh Osteochondral Allograft Transplantation of the Tibiotalar Joint: A Concise Mid-Term Follow-up of a Previous Report★.

Michael H French1, Julie C McCauley1, Pamela A Pulido1, Michael E Brage2, William D Bugbee1.   

Abstract

Despite advances in managing degenerative arthritis of the ankle joint, there are few optimal treatment options for young patients with symptomatic, end-stage degenerative disease. Popular surgical options consist of traditional arthrodesis and, more recently, arthroplasty. Additional techniques, including arthroscopic debridement and joint distraction, have gained little traction. An alternative option is bipolar fresh osteochondral allograft (OCA) transplantation of the tibiotalar joint. We previously reported on a cohort of 86 ankles that had undergone bipolar OCA of the tibiotalar joint and now present the results after longer, mid-term follow-up (mean, 9.2 years) of the same cohort. OCA survivorship was 74.8% at 5 years and 56% at 10 years. Of the patients with a surviving graft, 74% were satisfied with the results. At the latest follow-up, 86% reported better function and 79% reported less pain compared with preoperatively. Bipolar OCA transplantation of the tibiotalar joint is an effective alternative treatment for selected young patients with end-stage ankle arthritis who wish to avoid arthrodesis or prosthetic arthroplasty. LEVEL OF EVIDENCE:: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2019        PMID: 31045670     DOI: 10.2106/JBJS.18.01001

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  1 in total

1.  Outcomes Associated With Osteochondral Allograft Transplantation in Dogs.

Authors:  Samuel P Franklin; Aaron M Stoker; Sean M Murphy; Michael P Kowaleski; Mitchell Gillick; Stanley E Kim; Michael Karlin; Alan Cross; James L Cook
Journal:  Front Vet Sci       Date:  2021-12-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.